The commission shall publish on the commission’s Internet website any decisions on preferred drug list placement, including:
(1) a list of drugs reviewed and the commission’s decision for or against placement on a preferred drug list of each drug reviewed;
(2) for each recommendation, whether a supplemental rebate agreement or a program benefit agreement was reached under § 531.070; and
(3) the rationale for any departure from a recommendation of the Drug Utilization Review Board under § 531.0736.

Text of section effective until April 01, 2025